Health systems’ rare rejection of Alzheimer’s drug sparks questions about FDA approvals

Medical centers declining to administer an FDA-approved drug is rare, and controversy surrounding the Alzheimer’s drug Aduhelm has led to questions about the approval process, and even value-based care.